Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan Cardiac Repolarization Study
NCT05758818Phase 1Terminated
- Sponsor
- Rain Oncology Inc.
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of milademetan in Liposarcoma (3 arms), sponsored by Rain Oncology Inc. Primary endpoints: Number of participants with adverse events (AEs) up to 25 days, Incidence of laboratory abnormalities based on hematology test results up to 25 days and 4 more. Started Apr 2023; status: terminated.
02
Drugs
milademetan
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NCT05758818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05758818.